Larimar Therapeutics, Inc.
LRMR
$4.36
-$0.19-4.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.83% | 22.16% | 25.34% | 15.33% | 30.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.98% | 86.38% | 120.96% | 76.65% | 155.71% |
| Operating Income | -12.98% | -86.38% | -120.96% | -76.65% | -155.71% |
| Income Before Tax | -21.06% | -99.82% | -121.84% | -71.00% | -158.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.06% | -99.82% | -121.84% | -71.00% | -158.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.06% | -99.82% | -121.84% | -71.00% | -158.51% |
| EBIT | -12.98% | -86.38% | -120.96% | -76.65% | -155.71% |
| EBITDA | -13.03% | -86.74% | -121.69% | -77.24% | -156.83% |
| EPS Basic | -20.62% | -67.32% | -52.65% | -17.63% | -77.86% |
| Normalized Basic EPS | -20.62% | -67.31% | -52.59% | -17.67% | -77.92% |
| EPS Diluted | -20.62% | -67.32% | -52.65% | -17.63% | -77.86% |
| Normalized Diluted EPS | -20.62% | -67.31% | -52.59% | -17.67% | -77.92% |
| Average Basic Shares Outstanding | 0.35% | 19.44% | 45.34% | 45.33% | 45.34% |
| Average Diluted Shares Outstanding | 0.35% | 19.44% | 45.34% | 45.33% | 45.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |